Analytical Data
-
Gene name
VCAM-1/CD106
- Application
-
Alternative Names
CD106; INCAM-100; L1CAM
-
Species
Dog
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q28260
-
Expression Region
Thr136~Pro372
-
Molecular Weight
30kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
VCAM-1 (Vascular Cell Adhesion Molecule-1), also known as CD106, is an important adhesion molecule that plays a critical role in the inflammatory response and the recruitment of leukocytes to sites of inflammation. It is primarily expressed on endothelial cells and interacts with integrins on leukocytes, facilitating their adhesion and transmigration across the vascular endothelium. The study of VCAM-1/CD106 recombinant protein has garnered significant attention due to its involvement in various pathological conditions, including atherosclerosis, rheumatoid arthritis, and cancer metastasis. Researchers are particularly interested in the structural and functional properties of this molecule to better understand its role in immune cell trafficking and its potential as a therapeutic target. Moreover, recombinant VCAM-1 can be utilized in various experimental applications, such as studying cell adhesion mechanisms, developing diagnostic tools, and evaluating new drug candidates aimed at modulating inflammatory responses. By generating VCAM-1/CD106 recombinant proteins, scientists can create models to investigate its interactions with ligands and receptors, advancing our understanding of vascular biology and disease processes. Overall, the study of VCAM-1/CD106 recombinant protein holds promise for contributing to novel therapeutic strategies aimed at treating inflammatory diseases and improving vascular health.
